Who are NED Biosystems's investors?

NED Biosystems's investors include First Round Capital.

How much funding has NED Biosystems raised?

NED Biosystems has disclosed $1.5M raised across 1 round.

Where is NED Biosystems headquartered?

NED Biosystems is headquartered in Washington, US.

NED Biosystems

Washington, US · Delaware corporation · 1 known investors

NED Biosystems develops patented, non-toxic combination cancer treatments using a systems biology approach targeting multiple disease pathways simultaneously. The company's lead program NED-170 is designed for late-stage cancer patients, particularly those who are heavily pre-treated, with a focus on achieving no evidence of disease while minimizing toxicity and side effects.

Biotech Healthtech Medical Devices

Founders & leadership

Rebecca LambertinFounder

Peter D'ErricoExecutive

Board

Mary G. DavisBoard director

Randall S. BarkoBoard director

Holly T. SargentBoard director

Investors · 1

First Round Capital✓ verifiedSan Francisco · $1M – $7M

Reported raises · per SEC filings

Form D private placements

$1.5M disclosed across 1 round · 2015

▶$1.5MraisedOct 2015 · 12 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Rebecca LambertExecutive Officer, Director
Peter D'ErricoExecutive Officer
Mary G. DavisDirector
Randall S. BarkoDirector
Holly T. SargentDirector

Offering amount: $2M
Amount sold: $1.5M
First sale: Oct 2015
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

MD Anderson Cancer Center7 shared keywordsUT MD Anderson is a cancer research and treatment center that provides patient care, conducts research, and offers education in cancer prevention and treatment. It is part of the University of Texas System and operates as a nonprofit medical institution.

Companies competing with NED Biosystems for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does NED Biosystems do?: NED Biosystems develops patented, non-toxic combination cancer treatments using a systems biology approach targeting multiple disease pathways simultaneously. The company's lead program NED-170 is designed for late-stage cancer patients, particularly those who are heavily pre-treated, with a focus on achieving no evidence of disease while minimizing toxicity and side effects.
Who are NED Biosystems's investors?: NED Biosystems's investors include First Round Capital.
How much funding has NED Biosystems raised?: NED Biosystems has disclosed $1.5M raised across 1 round.
Where is NED Biosystems headquartered?: NED Biosystems is headquartered in Washington, US.